Short antisense compounds with gapmer configuration
View Patent ↗The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
1. A method of inhibiting a target nucleid acid in a cell in an animal comprising administering to the animal a compound comprising a short antisense oligonucleotide consisting of 12 to 14 linked nucleosides and having:
a gap region consisting of 8 to 12 linked 2′-deoxynucleosides;
a 5′-wing region adjacent to the gap region at the 5′ side of the gap region and consisting of 1 to 3 linked modified nucleosides; and
a 3′-wing region adjacent to the gap region at the 3′ side of the gap region and consisting of 1 to 3 linked modified nucleosides; wherein
at least one modified nucleoside of one or both of the 5′-wing region and the 3′-wing region is a high-affinity modified monomer; and thereby inhibiting the target nucleic acid in the cell in the animal.
2. The method of claim 1 , wherein the short antisense oligonucleotide consists of 12 linked nucleosides.
3. The method of claim 1 , wherein the short antisense oligonucleotide consists of 13 linked nucleosides.
4. The method of claim 1 , wherein the short antisense oligonucleotide consists of 14 linked nucleosides.
5. The method of claim 1 , wherein the gap region consists of 8 linked 2′-deoxynucleosides.
6. The method of claim 1 , wherein the gap region consists of 9 linked 2′-deoxynucleosides.
7. The method of claim 1 , wherein the gap region consists of 10 linked 2′-deoxynucleosides.
8. The method of claim 1 , wherein the gap region consists of 11 linked 2′-deoxynucleosides.
9. The method of claim 1 , wherein the gap region consists of 12 linked 2′-deoxynucleosides.
10. The method of claim 1 , wherein the short antisense oligonucleotide has a motif selected from 1-10-1; 2-10-1; 1-10-2; 2-10-2; and 2-8-2 wherein, the first number represents the number of modified nucleosides in the 5′-wing region, the second number represents the number of linked 2′-deoxynucleosides in the gap region, and the third number represents the number of modified nucleosides in the 3′-wing region.
11. The method of claim 10 , wherein the motif is selected from 1-10-1; 2-10-2; and 2-8-2.
12. The method of claim 1 , wherein the short antisense compound comprises at least one modified internucleoside linkage.
13. The method claim 12 , wherein the short antisense compound comprises at least one phosphorothioate linkage.
14. The method of claim 12 , wherein each internucleoside linkage of the short antisense oligonucleotide is a modified internucleo side linkage.
15. The method claim 14 , wherein each modified internucleoside linkage is a phosphorothioate linkage.
16. The method of claim 1 , wherein each modified nucleoside of one or both of the 5′-wing region and the 3′-wing region is a sugar-modified nucleotide comprising a bridge between the 4′ and 2′ position of the sugar.
17. The method of claim 1 , wherein each modified nucleoside of both the 5′-wing region and the 3′-wing region is a sugar-modified nucleotide comprising a bridge between the 4′ and 2′ position of the sugar.
18. The method of claim 17 , wherein the short antisense oligonucleotide consists of 12 linked nucleosides.
19. The method of claim 17 , wherein the short antisense oligonucleotide consists of 13 linked nucleosides.
20. The method of claim 17 , wherein the short antisense oligonucleotide consists of 14 linked nucleosides.
21. The method of claim 17 , wherein the gap region consists of 8 linked 2′-deoxynucleosides.
22. The method of claim 17 , wherein the gap region consists of 9 linked 2′-deoxynucleosides.
23. The method of claim 17 , wherein the gap region consists of 10 linked 2′-deoxynucleosides.
24. The method of claim 17 , wherein the gap region consists of 11 linked 2′-deoxynucleosides.
25. The method of claim 17 , wherein the gap region consists of 12 linked 2′-deoxynucleosides.
26. The method of claim 17 , wherein the short antisense oligonucleotide has a motif selected from 1-10-1; 2-10-1; 1-10-2; 2-10-2; 3-8-3; 2-8-3; 3-8-2; and 2-8-2 wherein, the first number represents the number of modified nucleosides in the 5′-wing region, the second number represents the number of 2′-deoxynucleosides in the gap region, and the third number represents the number of modified nucleosides in the 3′-wing region.
27. The method of claim 26 , wherein the motif is selected from 1-10-1; 2-10-2; and 2-8-2.
28. The method of claim 17 , wherein the short antisense compound comprises at least one modified internucleoside linkage.
29. The method claim 28 , wherein the short antisense compound comprises at least one phosphorothioate linkage.
30. The method of claim 28 , wherein each internucleoside linkage of the short antisense oligonucleotide is a modified internucleo side linkage.
31. The method claim 30 , wherein each modified internucleoside linkage is a phosphorothioate linkage.
32. The method of claim 1 , wherein the target nucleic acid is a target mRNA.
33. The method of claim 1 , wherein the target nucleic acid is a target pre-mRNA.
34. The method of claim 1 , wherein the target nucleic acid is from an infectious agent.
35. The method of claim 1 , wherein the target nucleic acid is cleaved.
36. The method of claim 1 , wherein the animal is a human.
37. The method of claim 1 , wherein each high-affinity modified monomer is a 2′-modified nucleotide.
38. The method of claim 37 , wherein each high-affinity modified monomer is a bicyclic nucleotide.
39. The method of claim 37 , wherein each 2′-modified nucleotide comprises a 2′ modification independently selected from halogen, allyl, amino, azido, thio, O-allyl, O—C 1 -C 10 alkyl, —OCF 3 , O—(CH 2 ) 2 —O—CH 3 , 2′-O(CH 2 ) 2 SCH 3 , O—(CH 2 ) 2 —O—N(R m )(R n ) or O—CH 2 —C(═O)—N(R m )(R n ), where each R m and R n is, independently, H or substituted or unsubstituted C 1 -C 10 alkyl.
40. The method of claim 1 , wherein at least one modified nucleoside of one or both of the 5′-wing region and the 3′-wing region comprises a 2′-O(CH 2 ) 2 OCH 3 substituent.
41. The method of claim 16 , wherein each of said bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R 1 )(R 2 )] n —, —C(R 1 )═C(R 2 )—, —C(R 1 )═N—, —C(═NR 1 )—, —C(═O)—, —C(═S)—, —O—, —Si(R 1 ) 2 —, —S(═O) x — and —N(R 1 )—;
wherein
x is 0, 1, or 2;
n is 1, 2, 3, or 4;
each R 1 and R 2 is, independently, H, a protecting group, hydroxyl, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5 -C 7 alicyclic radical, substituted C 5 -C 7 alicyclic radical, halogen, OJ 1 , NJ 1 J 2 , SJ 1 , N 3 , COOJ 1 , acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O) 2 -J 1 ), or sulfoxyl (S(═O)-J 1 ); and
each J 1 and J 2 is, independently, H, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C 1 -C 12 aminoalkyl, substituted C 1 -C 12 aminoalkyl or a protecting group.
42. The method of claim 41 , wherein at least one bridge comprises 4′-CH 2 —O -2′.
43. The method of claim 17 , wherein each of said bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R 1 )(R 2 )] n —, —C(R 1 )═C(R 2 )—, —C(R 1 )═N—, —C(═NR 1 )—, —C(═O)—, —C(═S)—, —O—, —Si(R 1 ) 2 —, —S(═O) x — and —N(R 1 )—;
wherein
x is 0, 1, or 2;
n is 1, 2, 3, or 4;
each R 1 and R 2 is, independently, H, a protecting group, hydroxyl, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 20 aryl, substituted C 5 -C 20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C 5 -C 7 alicyclic radical, substituted C 5 -C 7 alicyclic radical, halogen, OJ 1 , NJ 1 J 2 , SJ 1 , N 3 , COOJ 1 , acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O) 2 -J 1 ), or sulfoxyl (S(═O)-J 1 ); and
each J 1 and J 2 is, independently, H, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, substituted C 2 -C 12 alkynyl, C 5 -C 2o aryl, substituted C 5 -C 20 aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C 1 -C 12 aminoalkyl, substituted C 1 -C 12 aminoalkyl or a protecting group.
44. The method of claim 43 , wherein at least one bridge comprises 4′-CH 2 —O-2′.